Navigation Links
Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Date:8/20/2007

patented by Quark. The Company has licenses for certain RNAi intellectual property from Alnylam and Silence Therapeutics

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics based on its proprietary gene discovery science and technology, with an initial focus on drug candidates that work through the natural mechanism in the cell known as RNA interference, or RNAi, for the treatment of diseases associated with oxidative stress. Quark believes that its proprietary target gene discovery platform, BiFAR(TM), combined with its ability to design and successfully deliver synthetic molecules of the new class of RNAi therapeutics known as small-interfering RNA, or siRNA, to specific organs in the body, enables the Company to rapidly develop drug candidates. Quark has two internally discovered and developed lead product candidates: RTP801i-14 in phase 1 clinical trial for the treatment of wet age-related macular degeneration, and AKIi-5 for the prevention of acute renal failure. The Company has licensed RTP801i-14 to Pfizer on an exclusive worldwide basis. Quark has, in addition, a product candidate portfolio of RNAi therapeutics based on novel targets and therapeutic concepts discovered using BiFAR(TM) and designed for the treatment of oxidative stress associated diseases of the inner ear, lungs and additional organs of the body.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at http://www.quarkpharma.com

Forward-looking statement

Various statements in this release concerning the Company's future expectations, plans and prospects, including its intention to publicly offer shares of its common stock, constitute forward-looking statements for the purposes
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...ewswire-FirstCall/ -- Watson Pharmaceuticals, Inc....ceutical company, today confirmed that its subsidi...bbreviated New Drug Application (ANDA) with the U....o market its 8mg ramelteon tablets prior to the ex...l Company Limited. Watson,s 8mg ramelteon tablet ...
(Date:12/4/2009)...wswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) to...tion (FDA) has approved once-daily SEROQUEL XR...as adjunctive (add-on) treatment to antidepressant...SEROQUEL XR is the only medication in its class ap...isorder as adjunctive therapy and acute depressive...
(Date:12/3/2009)... COLLEGE, Pa., Dec. 3 Ambry Geneti... an agreement to provide extended bioinformatics g...ware for next-generation sequencing projects perfo....com/cgi-bin/prnh/20090428/LA06744LOGO ) ,, Anj...Ambry has been providing genomics solutions on Ill...
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 1Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 2Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 3Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 4Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 49180 1Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 49180 2Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 49180 3Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 49180 4Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 49180 5Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 49180 67 Proven Steps 3A How to Defeat Stress Without Going Through the Embarrassment of Counseling 3A Proven Ways to Defeat Stress 49176 17 Proven Steps 3A How to Defeat Stress Without Going Through the Embarrassment of Counseling 3A Proven Ways to Defeat Stress 49176 27 Proven Steps 3A How to Defeat Stress Without Going Through the Embarrassment of Counseling 3A Proven Ways to Defeat Stress 49176 3
...in Previous Nonresponders also Reported, KENILWOR...SE: SGP ) today provided an update on the clinica...ational oral hepatitis C,protease inhibitor. Initi...ment-naive (previously untreated) hepatitis C pati... with PEGINTRON(TM) (peginterferon,alfa-2b) and RE...
...son Addresses Executives Before Day-Long ...17 Representatives from more than 50,Greater Wash...aster,preparedness specialists from Deloitte & Tou...f Greater Washington (Roundtable), the American Re...r for Disability Special,Needs and Preparedness, a...
Other Medicine Technology:Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 9Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 2Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 3Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 4
(Date:12/4/2009)... -- Medithrive, Inc. has won the Patient,s Choice ...a by popular vote conducted by the online website,...operation, the SF Bay community has selected Medit...icinal marijuana. ,, The rapid rise and popul...sary which caters to the consumer, provides a beau...
(Date:12/4/2009)...re/ -- The large, two-day free health clinic spons...NAFC) in Kansas City on Wednesday and Thursday is ...ninsured and has not seen a doctor recently. All p...entive primary care. ,, "Many people who atten...is fall in Houston, New Orleans and Little Rock fo...
(Date:12/4/2009)...wswire/ -- In response to the U.S. Justice Depart...n of boldione, desoxymethyltestosterone, and 19-no...", under the Controlled Substances Act (CSA), John...oducts Association (NPA), the oldest and largest ...acturers of dietary supplements and other natural ...
(Date:12/4/2009)...from the School of Medicine,s Department of Nutrit...h products of lipid peroxidation and some drugs of...The pathways were identified by a combination of m...ings shed new light on the mechanism of action of ...n as "the date rape drug." The manuscript publishe...
(Date:12/4/2009)...y or 3 weeks later, study shows , , FRID...repair or reconstruction of multiple-ligament knee...udy has found. , Multiple-ligament knee injurie... occur in high-impact car crashes or in certain sp...r these injuries hasn,t been definitively establis...
Breaking Medicine News(10 mins):Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2
...dinburgh Royal Infirmary's accident and emergency ...where else in Scotland to be seen by a doctor.// ...ospital chiefs who face mounting criticism over cl...at more than a third of patients attending A&E spe...
...he rate of people admitted into hospitals with dia...new report by the Australian Institute of Health a...n O'Brien, says that the study shows that between ...diabetes, it is increasing in the community and so...
...he latest study by the UC Davis researchers states...crease their nutrition values by choosing better a...vis team, which is being published in the Septembe...es that need to be changed in order to improve the...
...eports have shown that the number of people dying ... pledge by the government 2002 to reduce the death...stics now show that deaths from heroin, cocaine an... concentrating on the wrong policy-making issues. ...
...ccording to the findings of a UCSF study to be pub..."Obstetrics and Gynecology," the risk of miscarria...est to identify genetic // or chromosomal abnormal...ed during the first and second trimester of pregna...
...oston: U.S. scientists at Harvard Medical School's...out a visual device that may prove a boon// to peo...o gauge the success rate of the high-tech device, ...h comprises of a small camera, pocket-sized comput...
Other Medicine News:Health News:Inordinately Long Waiting Times at A&E Infirmary 2Health News:Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks 2Health News:Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks 3Health News:Despite The Governments Vow Drug Death Rates On The Rise In UK 2Health News:Prenatal Test and Miscarriage 2Health News:Prenatal Test and Miscarriage 3
BioLon
...isc is the right viscoelastic agent for the surgeo...extracap technique. Amvisc possesses sufficient vi...ens removal. Amvisc is highly cohesive so that com... quickly accomplished. Amvisc is priced to compete...
...lon GV is a sterile, non-pyrogenic, transparent vi...flammatory, high molecular weight (average = 5 mil...on GV contains 14 mg/mL of sodium hyaluronate 7000...sphate buffer (pH 7.0-7.5). This polymer consists ...
...lon is a sterile, nonpyrogenic, viscoelastic prepa... molecular weight fraction of sodium hyaluronate.,...te dissolved in physiological sodium chloride phos...ght polymer is made up of repeating disaccharide u...
Medicine Products: